280 RESULTS
Sort By:
Combination Drug Trials: Time to Open a New Front in AD? Combination Trials: FDA Puts Flesh on Bones of Draft Guidance Combination Trials: Companies Can Play Well in One Sandbox Building a Roadmap for Shared Combination Drug Trials ACT-AD FDA/AD Allies Me
It’s a scenario familiar to many clinicians: A patient diagnosed with mild cognitive impairment asks if he or she will eventually develop Alzheimer’s disease.
As potential AD drugs continue to post disappointing Phase 2/3 results, many in the field are considering upping the artillery by testing experimental drugs in combination.
After more than a decade in the works, the long-awaited fifth edition of the Diagnostic and Statistical Manual of Mental Disorders (DSM-5) arrived last month to little fanfare.
Though iron gets a bad rap for accumulating in the brains of older people and individuals with neurodegenerative disease, could an abundance of this metal in the blood bode well?
Tiny blood vessels in the mouse brain crisscross the cortex, passing from one neural column to the next, like multiple streets between interconnecting city blocks...
Satori Pharmaceuticals, which had been developing γ-secretase modulators for the treatment of Alzheimer's disease, has closed its doors...
Brain atrophy plagues more than just people with neurodegenerative disorders...
Using carbon-14 to estimate the age of neurons, researchers calculate that the human brain produces around 700 new neurons per day...
Since the discovery of nucleotide repeats in the C9ORF72 gene, the hexanucleotides have presented a puzzle for scientists...
